Search

Background: Little is known about the adverse events (AEs) associated with coronavirus disease 2019 (COVID-19) vaccination in patients with type 2 diabetes mellitus (T2DM).Methods: This study used vaccine AE reporting system data to investigate severe AEs among vaccinated patients with T2DM. A natural language processing algorithm was applied to identify people with and without diabetes. After 1:3 matching, we collected data for 6,829 patients with T2DM and 20,487 healthy controls. Multiple logistic regression analysis was used to calculate the odds ratio for severe AEs.Results: After COVID-19 vaccination, patients with T2DM were more likely to experience eight severe AEs than controls: cerebral venous sinus thrombosis, encephalitis myelitis encephalomyelitis, Bell’s palsy, lymphadenopathy, ischemic stroke, deep vein thrombosis (DVT), thrombocytopenia (TP), and pulmonary embolism (PE). Moreover, patients with T2DM vaccinated with BNT162b2 and mRNA-1273 were more vulnerable to DVT and TP than those vaccinated with JNJ-78436735. Among patients with T2DM administered mRNA vaccines, mRNA-1273 was safer than BNT162b2 in terms of the risk of DVT and PE.Conclusion: Careful monitoring of severe AEs in patients with T2DM may be necessary, especially for those related to thrombotic events and neurological dysfunctions after COVID-19 vaccination.

ImportanceWhether ketamine is as effective as electroconvulsive therapy (ECT) among patients with major depressive episode remains unknown.ObjectiveTo systematically review and meta-analyze data about clinical efficacy and safety for ketamine and ECT in patients with major depressive episode.Data SourcesPubMed, MEDLINE, Cochrane Library, and Embase were systematically searched using Medical Subject Headings (MeSH) terms and text keywords from database inception through April 19, 2022, with no language limits. Two authors also manually and independently searched all relevant studies in US and European clinical trial registries and Google Scholar.Study SelectionIncluded were studies that involved (1) a diagnosis of depression using standardized diagnostic criteria, (2) intervention/comparator groups consisting of ECT and ketamine, and (3) depressive symptoms as an efficacy outcome using standardized measures.Data Extraction and SynthesisData extraction was completed independently by 2 extractors and cross-checked for errors. Hedges g standardized mean differences (SMDs) were used for improvement in depressive symptoms. SMDs with corresponding 95% CIs were estimated using fixed- or random-effects models. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was followed.Main Outcomes and MeasuresEfficacy outcomes included depression severity, cognition, and memory performance. Safety outcomes included serious adverse events (eg, suicide attempts and deaths) and other adverse events.ResultsSix clinical trials comprising 340 patients (n = 162 for ECT and n = 178 for ketamine) were included in the review. Six of 6 studies enrolled patients who were eligible to receive ECT, 6 studies were conducted in inpatient settings, and 5 studies were randomized clinical trials. The overall pooled SMD for depression symptoms for ECT when compared with ketamine was −0.69 (95% CI, −0.89 to −0.48; Cochran Q, P = .15; I2 = 39%), suggesting an efficacy advantage for ECT compared with ketamine for depression severity. Significant differences were not observed between groups for studies that assessed cognition/memory or serious adverse events. Both ketamine and ECT had unique adverse effect profiles (ie, ketamine: lower risks for headache and muscle pain; ECT: lower risks for blurred vision, vertigo, diplopia/nystagmus, and transient dissociative/depersonalization symptoms). Limitations included low to moderate methodological quality and underpowered study designs.Conclusions and RelevanceFindings from this systematic review and meta-analysis suggest that ECT may be superior to ketamine for improving depression severity in the acute phase, but treatment options should be individualized and patient-centered.

Objective: The World Health Organization (WHO) declared a pandemic on March 11, 2020 after more than 118,000 cases of coronavirus disease 2019 (COVID-19) had been reported in 114 countries. Our study analyzed the cumulative incidence rate based on WHO data starting with the first confirmed patient until the peak of transmission. In addition, the numerical values of nasometry from normal subjects were quantified to analyze the linguistic features.Methods: This study consisted of two main methodologies including a meta-analysis based on nasometry data involving normal adults and cumulative incidence rate based on WHO data. In addition, the numerical values of nasometry from normal subjects were quantified to analyze the linguistic features.Results: The pooled overall mean differences (MDs) for oral text nasalance among linguistic families were 14.655 (95% confidence interval [CI], 7.986–21.324) in Arabic, 24.441 (95% CI, 17.920–30.962) in Chinese, 14.964 (95% CI, 13.677–16.251) in European, and 11.437 (95% CI, 9.880–12.994) in Ural-Altaic. The pooled overall MDs for cumulative incidence rate of COVID-19 were 190.3 (95% CI, 56.10–324.60) in Arabic, 283.20 (95% CI, 1.80–564.60) in European, and 5.70 (95% CI, 4.90–6.60) in Ural-Altaic. Correlation between oral nasalance score and cumulative incidence was significant (P=0.0004).Conclusion: Our study showed the possible association between language characteristics and early spread of COVID-19. Further studies are needed to validate our outcomes based on various epidemiologic and behavioral factors including mask wearing.

Recent randomized controlled trials (RCTs) examined the role of adding androgen receptor signaling inhibitors (ARSIs), including abiraterone acetate (ABI), apalutamide, darolutamide (DAR), and enzalutamide (ENZ), to docetaxel (DOC) and androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).To analyze the oncologic benefit of triplet combination therapies using ARSI + DOC + ADT, and comparing them with available treatment regimens in patients with mHSPC.Three databases and meetings abstracts were queried in April 2022 for RCTs analyzing patients treated with first-line combination systemic therapy for mHSPC. The primary interests of measure were overall survival (OS) and progression-free survival (PFS). Subgroup analyses were conducted to assess the differential outcomes in patients with low- and high-volume disease as well as de novo and metachronous metastasis.Overall, 11 RCTs were included for meta-analyses and network meta-analyses (NMAs). We found that the triplet combinations outperformed DOC + ADT in terms of OS (pooled hazard ratio [HR]: 0.74, 95% confidence interval [CI]: 0.65-0.84) and PFS (pooled HR: 0.49, 95% CI: 0.42-0.58). There was no statistically significant difference between patients with low- and high-volume disease in terms of an OS benefit from adding an ARSI to DOC +ADT (both HR: 0.79; p = 1). Based on NMAs, triplet therapy also outperformed ARSI + ADT in terms of OS (DAR + DOC + ADT: pooled HR: 0.74, 95% CI: 0.55-0.99) and PFS (ABI + DOC + ADT: HR: 0.68, 95% CI: 0.51-0.91, and ENZ + DOC + ADT: HR: 0.70, 95% CI: 0.53-0.93). An analysis of treatment ranking among de novo mHSPC patients showed that triplet therapy had the highest likelihood of improved OS in patients with high-volume disease; however, doublet therapy using ARSI + ADT had the highest likelihood of improved OS in patients with low-volume disease.We found that the triplet combination therapy improves survival endpoints in mHSPC patients compared with currently available doublet treatment regimens. Our findings need to be confirmed in further head-to-head trials with longer follow-up and among various patient populations.Our study suggests that triplet therapy with androgen receptor signaling inhibitor, docetaxel, androgen deprivation therapy prolongs survival in patients with metastatic hormone-sensitive prostate cancer compared with the current standard doublet therapy.

The purpose of the current study was to evaluate the diagnostic accuracies of 18 F-FDG PET or PET/CT for diagnosis of Merkel cell carcinoma (MCC) through a systematic review and meta-analysis.The PubMed, Cochrane database, and EMBASE database, from January 1990 to January 31, 2022, were searched for studies evaluating diagnostic performance of 18 F-FDG PET or PET/CT for MCC. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic curves.Across 9 studies (259 patients), the pooled sensitivity of 18 F-FDG PET or PET/CT was 0.91 (95% confidence interval [CI], 0.85-0.95) and a pooled specificity of 0.93 (95% CI, 0.86-0.97). Likelihood ratio syntheses gave an overall LR+ of 14.0 (95% CI, 6.6-29.6) and LR- of 0.09 (95% CI, 0.05-0.17). The pooled diagnostic odds ratio was 153 (95% CI, 57-416).18 F-FDG PET/CT showed an excellent performance for diagnosis of MCC. The likelihood ratio scattergram indicated that 18 F-FDG PET or PET/CT is useful for exclusion and confirmation of MCC. Further large multicenter studies would be necessary to substantiate the diagnostic accuracy of 18 F-FDG PET or PET/CT for MCC patients.

To evaluate the prognostic value of albumin-to-alkaline phosphatase ratio (AAPR) on recurrence and survival in patients with non-metastatic renal cell carcinoma (RCC) treated with radical or partial nephrectomy.Between June 1994 and December 2018, 491 patients with RCC who underwent radical or partial nephrectomy at 2 institutions were enrolled in this study. Recurrence-free survival (RFS) and cancer-specific survival (CSS) analyses were performed to distinguish the differences in postoperative recurrence and survival between patients stratified by an optimal cut-off value of AAPR. Multivariable Cox proportional hazards regression models were established to determine the independent prognostic factors after propensity score weighting.Of the total 491 patients, 51 patients (10.4%) developed local recurrence or distant metastasis and 26 patients (5.3%) died of disease during the follow-up period. Patients with AAPR0.41 had significantly lower rates of RFS and CSS than those of patients with AAPR≥0.41 in multivariate analysis (P.001 and P = .027, respectively). After propensity scroe matching analyses, this difference was still remained for RFS (P.001). However, AAPR was not an independent prognostic factor for CSS but the value was almost pregnant (HR = 2.674; 95%CI = 0.872-8.203; P = .086).AAPR can serve as a novel and useful tool to refine prognosis in patients with non-metastatic RCC treated with partial or radical nephrectomy. These findings suggest that AAPR could be a promising prognostic factor for prediction of recurrence and survival in patients with non-metastatic RCC who undergo nephrectomy.

Purpose To verify the dose-response relation between degree of myopia and open-angle glaucoma (OAG) risk Design Dose-response meta-analysis Methods We searched the PubMed, EMBASE, and Cochrane databases for population-based studies published until 30 November 2020 and reporting on both myopia and OAG. Random-effect models generated pooled odds ratios (OR) and 95% confidence intervals (CIs). Results robustness was confirmed by influence and subgroup analyses. A two-stage dose-response meta-analysis (DRMA) calculated the OAG risk per unit dose of myopia (spherical equivalent [SE] decrease of 1 diopter [D]) and examined the relationship pattern. Results Twenty-four (24) studies in 11 countries (514,265 individuals) made up the meta-analyses. The pooled OR of any myopia degree's association with OAG was 1.88 (95% CI, 1.66–2.13; I2=53%). The OR differences based on ethnicity (Asians vs. Westerners) or 5 geographic areas were not statistically significant (P=0.80 and 0.06, respectively). The pooled ORs of the associations between low, moderate, moderate-to-high, high myopia, and OAG were 1.50 (95% CI, 1.29–1.76), 1.69 (1.33–2.15), 2.27 (1.74–2.96), and 4.14 (2.57–6.69), respectively. According to the DRMA, the pooled OR (per SE 1 D change) was 1.21 (95% CI, 1.15–1.28); the OAG risk accelerated at around –6 D, and further accelerated from –8 D, showing a non-linear concave upward slope (P=0.03). Conclusions We found that for each unit (1 D) increase in myopia, the risk of glaucoma increases by approximately 20%. The risk more steeply increases in high-degree myopia, representing a significant non-linear relationship.

Topic Comparative efficacy and safety of different concentrations of atropine for myopia control in children. Clinical relevance Atropine is known to be an effective intervention to delay childhood myopia progression. Nonetheless, there is as yet no well-supported evidence ranking the clinical outcomes of various concentrations of atropine. Methods We searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials, WHO International Clinical Trials Registry Platform and ClinicalTrials.gov on Apr 14, 2021. We selected studies involving atropine treatment of at least 1-year duration for control of myopia in children. We performed a network meta-analysis (NMA) of placebo-controlled and head-to-head randomized controlled trials (RCTs) and compared 8 atropine concentrations (1, 0.5, 0.25, 0.1, 0.05, 0.025, 0.02, and 0.01%). We ranked the atropine concentrations for the corresponding outcomes by P-score (estimate of probability of being best treatment). Our primary outcomes were mean annual changes in refraction (diopters/year) and axial length ([AXL] millimeters/year). We also extracted data on the proportion of eyes showing myopia progression and safety outcomes (photopic/mesopic pupil diameter, accommodation amplitude, distance/near best-corrected visual acuity [BCVA]). Results Thirty (30) pairwise comparisons from 16 RCTs (3,272 participants) were obtained. Our NMA ranked the 1, 0.5 and 0.05% atropine concentrations as the 3 most beneficial for myopia control based on P-scores, as assessed for both primary outcomes: 1% atropine (mean difference and 95% CI in refraction compared to control: 0.81 [0.58;1.04]; AXL: -0.35 [-0.46;-0.25]), 0.5% atropine (refraction: 0.70 [0.40;1.00]; AXL: -0.23 [-0.38;-0.07]), 0.05% atropine (refraction: 0.62 [0.17;1.07]; AXL: -0.25 [-0.44;-0.06]). In terms of myopia control as assessed by relative risk (RR) for overall myopia progression, 0.05% was ranked as the most beneficial atropine concentration (RR:0.39 [95% CI: 0.27;0.57]) followed by 1% (0.43 [0.33;0.56]). The ranking probability for adverse effects (photopic/mesopic pupil diameter and accommodation amplitude) tended to decline as the atropine concentration was increased, though this tendency was not evident for distance BCVA. No valid network was formed for near BCVA. Conclusion The ranking probability for efficacy was not proportional to dose (i.e., 0.05% atropine was comparable to that of high-dose [1 and 0.5%]), though those for pupil size and accommodation amplitude were dose-related.

CONTEXT: Several recent randomised trials have evaluated the role of combination systemic treatment using androgen deprivation therapy (ADT) plus chemotherapy or an androgen receptor signaling inhibitor (ARSI) in patients with high-risk and/or unfavourable nonmetastatic prostate cancer (nmPC). OBJECTIVE: To assess the outcomes associated with adding combination systemic treatment to primary definitive local therapy in patients with high-risk and/or unfavourable nmPC. EVIDENCE ACQUISITION: We queried the PubMed, Web of Science, and Scopus databases and conference abstracts to identify prospective randomised trials examining the value of adding chemotherapy or an ARSI to ADT and primary local therapy with curative intent for nmPC. The primary endpoints were overall survival (OS), cancer-specific survival (CSS), metastasis-free survival (MFS), and failure-free survival (FFS). Secondary endpoints included adverse events (AEs) and pathologic outcomes. EVIDENCE SYNTHESIS: We identified 15 randomised studies, of which nine evaluated chemohormonal and six investigated ARSI-based treatment strategies. In both radical prostatectomy (RP) and radiation therapy (RT) settings, addition of docetaxel to ADT was associated with significantly better CSS (pooled hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.49-0.95; p = 0.025), MFS (pooled HR 0.82, 95% CI 0.71-0.95; p = 0.008), and FFS (pooled HR 0.70, 95% CI 0.62-0.79; p < 0.001); the difference did not meet the conventional level of statistical significance for OS (pooled HR 0.86, 95% CI 0.73-1.01; p = 0.072). For patients treated with RT alone, docetaxel-based combination treatment did not meet the significance threshold set for OS (p = 0.3), CSS (p = 0.072), or MFS (p = 0.079), but the difference for FFS was statistically significant (pooled HR 0.72, 95% CI 0.63-0.84; p < 0.001). On network meta-analyses including RT studies, ARSI + ADT outperformed docetaxel + ADT for survival endpoints and had a more favourable AE profile. CONCLUSIONS: Intensification of systemic therapy with docetaxel or an ARSI in addition to ADT improves oncologic endpoints in high-risk and/or unfavourable nmPC treated with local definitive therapy. The highest efficacy was achieved with ARSI + ADT, specifically in patients treated with RT. PATIENT SUMMARY: Our findings highlight that selected patients with high-risk nonmetastatic prostate cancer benefit from intensification of systemic therapy beyond hormonal treatment. ispartof: EUROPEAN UROLOGY vol:82 issue:1 pages:82-96 ispartof: location:Switzerland status: published

Cardiovascular disease (CVD) is one of the leading causes of death, accounting for one-third of all deaths worldwide. Patients with CVD are three times more likely to complain of sexual dysfunction than healthy people. Causes of sexual dysfunction in patients with CVD include physical/mental changes and drug side effects. The prevalence of sexual dysfunction in patients with CVD has been estimated to be up to 89%. Ordinary treatments such as pharmacotherapy cannot effectively reduce sexual problems. Therefore, sexual rehabilitation has a broad spectrum, including exercise therapy such as pelvic floor muscle treatment, appropriate counseling, a multidisciplinary approach, and partner rehabilitation. In this study, systematic review and meta-analysis was performed to investigate the effect of sexual rehabilitation on sexual problems in patients with CVD.Comprehensive literature searches were conducted using MEDLINE, Cochrane Library electronic database, and EMBASE through June 2022. Questionnaire scores at the end point as outcomes of the study were recorded as were standardized mean difference (SMD) with their 95% confidence intervals (CIs). Meta-regression analysis was conducted for each moderator. We performed a risk of bias evaluation for included studies using the RoB 2 tool.The overall SMD in the meta-analysis for sexual rehabilitation versus no-sexual rehabilitation was 0.430 (95% CI, 0.226-0.633). There was a statistical difference between groups. SMD changes were 0.674 (95% CI, 0.308-1.039) at one month and 0.320 (95% CI, 0.074-0.565) at six months. The regression analysis with all variables (number of patients, study duration, and questionnaire types) revealed no significance.This study indicates that sexual rehabilitation is an effective method with high therapeutic potential for sexual dysfunction of patients with CVD. However, for clinical application, well-designed studies with many patients should be conducted in the future and the standardization of rehabilitation protocols is required.

The aims of this study are to compare the performance of various preoperative imaging modalities for assessing the malignant potential of pancreatic cystic lesions (PCLs) through a network meta-analysis (NMA) and to clarify the role of 18 F-FDG PET in the management of patients with PCL.PubMed, EMBASE, and Cochrane Library were searched for the studies evaluating the performance of preoperative imaging modalities for identifying malignant PCLs. The NMA was performed for 4 representative categories of various imaging modalities in terms of diagnostic performance for differentiating malignant from benign PCL and intraductal papillary mucinous neoplasms only as a subgroup analysis. To calculate the probability of each imaging modality being the most effective diagnostic method, the surface under the cumulative ranking curve values were obtained.A total of 1018 patients from 17 direct comparison studies using 2 or more preoperative imaging modalities were included for differentiating malignant from benign PCL. The positive predictive value (PPV) and accuracy of 18 F-FDG PET were significantly higher than that of CT (PPV: odds ratio [OR], 2.66; 95% credible interval [CrI], 1.21-6.17; accuracy: OR, 2.63; 95% CrI, 1.41-5.38) or MRI (PPV: OR, 2.50; 95% CrI, 1.09-6.26; accuracy: OR, 2.50; 95% CrI, 1.28-5.47) in all PCLs, as well as in the subgroup analysis for intraductal papillary mucinous neoplasm only. 18 F-FDG PET showed the highest surface under the cumulative ranking curve values in all diagnostic performance areas of sensitivity, specificity, PPV, negative predictive value, and accuracy, followed by MRI or CT.The results from this NMA suggest that 18 F-FDG PET is the best preoperative imaging modality for differentiating malignant from benign PCLs and that it can be used for the preoperative evaluation of PCLs.

Objective This study aimed to compare diagnostic performances of 8 different imaging modalities for preoperative detection of axillary lymph node (LN) metastasis in patients with breast cancer by performing a network meta-analysis (NMA) using direct comparison studies with 2 or more imaging techniques. Materials and methods PubMed, Cochrane, and Embase were searched for the studies evaluating the performances of 8 different imaging modalities for preoperative axillary LN staging in patients with breast cancer. The NMA was performed in patient-based analyses. The consistency was evaluated by examining the agreement between direct and indirect treatment effects, and publication bias was assessed by funnel plot asymmetry tests. The surface under the cumulative ranking curve (SUCRA) values were obtained to calculate the probability of each imaging modality being the most effective diagnostic method. Results A total of 2197 patients from 22 direct comparison studies using 8 different imaging modalities for preoperative detection of axillary LN metastasis in patients with breast cancer were included. For preoperative detection of axillary LN metastasis of breast cancer, elastography showed the highest SUCRA values of sensitivity, specificity, positive predictive value, negative predictive value, accuracy, and diagnostic odds ratio. In addition, fluorine-18 fluorodeoxyglucose positron emission tomography (PET) or PET/computed tomography, fluorine-18 fluorodeoxyglucose PET/magnetic resonance, and contrast-enhanced computed tomography showed high SUCRA values. Conclusion Elastography showed the highest SUCRA values. Seven imaging modalities showed the complementary diagnostic roles for preoperative detection of axillary LN metastasis in patients with breast cancer, except mammography.

Introduction Suicide is an important public health problem. Well-established risk factors of suicide include depression, family history of mental disorders, substance problem, chronic physical illness, and others. Sensory impairment, especially visual impairment (VI), has a critical impact on both mental and physical health. However, the association between VI and risk of suicide has not been thoroughly investigated and remains controversial. Our aim is to systematically review and meta-analyze the current evidence on the association between VI and risk of suicide and to evaluate the direction and magnitude of the association. Methods and analysis We aim to search PubMed, EMBASE and the Cochrane Library to identify all population-based studies on the association between VI and risk of suicide. Two reviewers will independently conduct study selection, data extraction and risk of bias (ROB) assessment. The Newcastle-Ottawa scale will be applied to evaluate the methodologic quality of the included studies for ROB assessment. The primary outcome measure will be the relative risk (RR) of suicide, and the secondary outcome measures will be the risks of suicidal ideation (SI) and suicide attempt (SA). Estimates of risk with 95% confidence intervals (CIs) for suicide, SI and SA, respectively, will be calculated and summarized. We will perform random-effects meta-analyses to combine the pooled effects. Meta-regression will be applied to investigate the effects of multiple factors across studies. Subgroup and sensitivity analyses will be conducted for screening of any potential sources of heterogeneity. Publication bias will be evaluated by funnel plot and Begg and Mazumdar correlation testing. The body of evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. Conclusion This article presents a study protocol for investigating the association between VI and risk of suicide. The findings of this study will contribute to our current knowledge of the impact of VI as a risk factor of suicide. In addition, meta-regression and subgroup analyses will provide further insights to factors affecting the association between VI and suicide risk. Trial registration Systematic review registration: PROSPERO CRD 42022325106.

Background and Aims: The utility of clinical information from esophagogastroduodenoscopy (EGD) reports has been limited because of its unstructured narrative format. We developed a natural language processing (NLP) pipeline that automatically extracts information about gastric diseases from unstructured EGD reports and demonstrated its applicability in clinical research. Methods: An NLP pipeline was developed using 2000 EGD and associated pathology reports that were retrieved from a single healthcare center. The pipeline extracted clinical information, including the presence, location, and size, for 10 gastric diseases from the EGD reports. It was validated with 1000 EGD reports by evaluating sensitivity, positive predictive value (PPV), accuracy, and F1 score. The pipeline was applied to 248,966 EGD reports from 2010–2019 to identify patient demographics and clinical information for 10 gastric diseases. Results: For gastritis information extraction, we achieved an overall sensitivity, PPV, accuracy, and F1 score of 0.966, 0.972, 0.996, and 0.967, respectively. Other gastric diseases, such as ulcers, and neoplastic diseases achieved an overall sensitivity, PPV, accuracy, and F1 score of 0.975, 0.982, 0.999, and 0.978, respectively. The study of EGD data of over 10 years revealed the demographics of patients with gastric diseases by sex and age. In addition, the study identified the extent and locations of gastritis and other gastric diseases, respectively. Conclusions: We demonstrated the feasibility of the NLP pipeline providing an automated extraction of gastric disease information from EGD reports. Incorporating the pipeline can facilitate large-scale clinical research to better understand gastric diseases.

Air pollution and meteorological factors can exacerbate susceptibility to respiratory viral infections. To establish appropriate prevention and intervention strategies, it is important to determine whether these factors affect the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therefore, this study examined the effects of sunshine, temperature, wind, and air pollutants including sulfur dioxide (SO

Objective Previous systematic reviews evaluating the association between coffee consumption and pancreatic cancer showed inconsistent results. The aim was to conduct a meta-epidemiological study to explore further the association between coffee consumption and the incidence of pancreatic cancer. Methods The selection criteria were defined as a population-based prospective cohort study reporting adjusted relative risk (RR) and their 95% confidence interval (95%CI) of pancreatic cancer occurrence according to coffee consumption. Adjusted RR for the highest versus the lowest level of coffee consumption in each study was extracted. A fixed-effect model was applied to calculate a summary RR (sRR) and its 95%CI. Two-stage random-effects dose-response meta-analysis (DRMA) was performed to estimate the incidence risk per unit dose (cup per day). Results Twelve cohort studies were selected for meta-analysis. The total number of cohort participants was 3,230,053, and pancreatic cancer incidents were 10,587. The sRR of pancreatic cancer risk for the highest versus the lowest level of coffee consumption indicated no statistical significance (sRR=0.98, 95% CI: 0.88-1.10; I-squared=0.0%). Two-stage random-effect DRMA showed the non-linear relationship between the amount of coffee consumption and pancreatic cancer risk. And the RR for an increment of one cup per day of coffee consumption was 0.97 (95%CI: 0.91-1.04, P=0.42), without statistically significant. Conclusion There was no association between coffee consumption habits and pancreatic cancer risk. And there was no statistical significance in the dose-response relationship between the amount of coffee consumption and pancreatic cancer risk. Finding the turning point would be important because it can be critical information for the prevention of pancreatic cancer. .

To determine whether the existing literature provides evidence that curved path walking time can be a reliable marker of cognitive impairment among older adults using a network meta-analysis (NMA).PubMed, Web of Science, ScienceDirect, Scopus, and Korean Studies Information Service System (KSISS) electronic databases were searched in December 2019.Studies that included the following variables were selected: (P): patients with cognitive impairment, (I): straight path versus curved path walking, (C): control group without cognitive impairment, (O): walking time, and (S): cross-sectional or longitudinal study design. In total, 21 studies were selected for the NMA, which was performed to compare the standardized mean difference (SMD) of walking time on curved and straight paths.Older adults with dementia had significantly longer walking times than older adults with mild cognitive impairment (MCI) for both straight path walking and curved path walking. The SMD of straight path walking time was 0.59 (95% credible interval [CrI]: 0.39, 0.81) for older adults with MCI and 0.90 (95% CrI: 0.65, 1.16) for older adults with dementia. The SMD of walking time on a curved path was 0.52 (95% CrI: -0.22, 1.26) for older adults with MCI and 1.98 (95% CrI: 1.20, 2.92) for those with dementia. In older adults with dementia, the correlation coefficient of the Fisher's z value was higher for curved path walking than for straight path walking.The way people with dementia walk exhibits signs of cognitive impairments. NMA confirmed that older adults with dementia requires significantly longer time to walk the same distance than healthy controls or older adults with MCI for both curved and straight path walking.

To determine the effect of pelvic floor muscle exercise (PFME) for post-prostatectomy urinary incontinence (PPUI), which has a major impact on the quality of life of patients undergone radical prostatectomy (RP).A systematic search was conducted in the PubMed, Embase, and Cochrane Library databases from the inception of each database until April 2021. We performed a meta-analysis separately using the number of patients achieving urinary continence as binary data, and the patients' ICIQ-SF scores as continuous data. Odds ratios (ORs) and mean difference (MD) with 95% confidence intervals (CI) and a random-effects model were utilized to adequately analyze the overall recovery of UI. We performed a risk of bias evaluation on the included studies using the RoB 2 tool.Twenty-one studies met our selection criteria for quantitative synthesis. Eight studies were on the effects of PFME, and 13 studies were on the effects of assistant interventions added to PFME. The overall continence OR in the meta-analysis for PFME vs no-PFME was 2.971 (95% CI: 1.278, 6.907). The overall ICIQ-SF score in the meta-analysis for PFME vs no-PFME was -1.012 (95% CI: -2.379, 0.355). In case of assistant interventions added to PFME, the overall continence OR in the meta-analysis for assistant interventions vs conventional PFME only was 2.128 (95% CI: 1.357, 3.336).In our study, a positive effect of PFME on the recovery of PPUI was observed. However, more research with higher quality is needed to confirm the real efficacy of PFME.

Importance Whether radioactive iodine (RAI) therapy for hyperthyroidism can increase cancer risk remains a controversial issue in medicine and public health. Objectives To examine site-specific cancer incidence and mortality and to evaluate the radiation dose-response association after RAI treatment for hyperthyroidism. Data sources The Medline and Cochrane Library electronic databases, using the Medical Subject Headings terms and text keywords, and Embase, using Emtree, were screened up to October 2020. Study selection Study inclusion criteria were as follows: (1) inclusion of patients treated for hyperthyroidism with RAI and followed up until cancer diagnosis or death, (2) inclusion of at least 1 comparison group composed of individuals unexposed to RAI treatment (eg, the general population or patients treated for hyperthyroidism with thyroidectomy or antithyroid drugs) or those exposed to different administered doses of RAI, and (3) inclusion of effect size measures (ie, standardized incidence ratio [SIR], standardized mortality ratio [SMR], hazard ratio [HR], or risk ratio [RR]). Data extraction and synthesis Two independent investigators extracted data according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Overall quality assessment followed the recommendations of United Nations Scientific Committee on the Effects of Atomic Radiation. The SIR and SMRs and the RRs and HRs were pooled using random-effects meta-analysis. Main outcomes and measures Cancer incidence and mortality for exposure vs nonexposure to RAI therapy and by level of RAI administered activity. Results Based on data from 12 studies including 479 452 participants, the overall pooled cancer incidence ratio was 1.02 (95% CI, 0.95-1.09) and the pooled cancer mortality ratio was 0.98 (95% CI, 0.92-1.04) for exposure vs nonexposure to RAI therapy. No statistically significant elevations in risk were observed for specific cancers except thyroid cancer incidence (SIR, 1.86; 95% CI, 1.19-2.92) and mortality (SMR, 2.22; 95% CI, 1.37-3.59). However, inability to control for confounding by indication and other sources of bias were important limitations of studies comparing RAI exposure with nonexposure. In dose-response analysis, RAI was significantly associated with breast and solid cancer mortality (breast cancer mortality, per 370 MBq: 1.35; P = .03; solid cancer mortality, per 370 MBq: 1.14; P = .01), based on 2 studies. Conclusions and relevance In this meta-analysis, the overall pooled cancer risk after exposure to RAI therapy vs nonexposure was not significant, whereas a linear dose-response association between RAI therapy and solid cancer mortality was observed. These findings suggest that radiation-induced cancer risks following RAI therapy for hyperthyroidism are small and, in observational studies, may only be detectable at higher levels of administered dose.

The effects of urbanization on the health of city dwellers have spurred research on the health-promoting benefits of forest exposure, and potential health-promoting benefits of human-nature relationships. In this meta-analysis, meta-regression, and systematic review, we aimed to analyze how forest-based interventions improved overall well-being through psychological and physiological changes by examining psychological scores and biomarkers. In December 2021, systematic searches were conducted on bibliographic databases (PubMed, Embase, and Cochrane) for studies involving psychological scores and physiological indicators. Data from 17 studies with 1418 participants showed that psychological symptoms (anxiety, depression, anger, fatigue, confusion, vigor), systolic blood pressure (BP), and malondialdehyde levels significantly improved in the forest-exposed group compared to in the nonexposed group, with high heterogeneity (I2 = 66%–93%). Well-being-related psychological symptoms (friendliness, well-being, attention deficit hyperactivity disorder, self-esteem) and physiological markers (diastolic BP and cortisol) exhibited better tendencies in the forest-exposed group, with high heterogeneity (I2 = 16%–91%), and meta-regression showed that moderators (age, country group, number of participants, study design, female participation rate, BMI) were significantly associated with forest-related therapeutic effects. In conclusion, forest visits have health-promoting effects that reduce the incidence of stress and lifestyle-related diseases, and are positively associated with psychological and physiological health.

The objective of this study is to introduce how to use all of these information without omission when individual studies provide multiple effect sizes according to multiple cut-off values (thresholds) during diagnostic test meta-analysis for data integration. For diagnostic test meta-analysis, a general performance method of synthesizing data according to one cut value in one study and a performance method of synthesizing data according to two or more cut values in one study were compared and analyzed. In addition, this study focuses on the practical methods of DTA rather than theoretical concepts for researchers whose fields of study were non-statistics related. Through this, it is expected that general researchers will be able to use the already developed statistical tools to write and interpret them appropriately for their research fields. By performing this study, we hope that many researchers will use R software to determine the DTA more easily, and that there will be greater interest in related research.

Direct and indirect evidence were combined in this systematic-review and network meta-analysis (NMA) to assess and compare the effect of nutritional supplements on glycemic control, and rank the supplements accordingly.PubMed, Scopus, and Web of Science were searched up to April 2021. We included randomized controlled trials that investigated the effect of vitamins D, C, and E, magnesium, zinc, calcium, selenium, and omega-3 on at least one glycemic marker, including glycated hemoglobin (HbA1c), fasting blood sugar (FBS), homeostasis model assessment-estimated insulin resistance (HOMA-IR), HOMA-B, and insulin, in adults with type 2 diabetes. To estimate effectiveness of supplements, a random-effects NMA in the Bayesian framework was applied. To assess risk of bias, Cochrane Collaboration Tool was used.Analysis of 178 studies indicated that zinc, vitamin D, omega-3, vitamin C, and vitamin E were effective in reducing HbA1c with low certainty. For reduction of FBS, zinc, vitamin D, and vitamin C, and for HOMA-IR, vitamin D were effective with low certainty. None of the supplements were effective in the reduction of insulin and HOMA-B with low certainty. After excluding poor-quality studies, only vitamin D was significantly effective in reducing all of the markers. Consistently, when the analysis was restricted to studies with a duration of ≥12-weeks, vitamin D reduced HbA1c, FBS, and HOMA-IR.Vitamin D supplementation was more effective compared to other supplements in improving HbA1c, FBS, and HOMA-IR, albeit with low certainty of evidence. This result was confirmed by low-risk of bias studies.CRD42021240691.

Purpose: Investigation of myopic open-angle glaucoma (OAG) prevalence in Northeast Asia by systematic review and meta-analysis.Methods: Systematic PubMed, Embase and Cochrane database searches for Northeast Asian population-based studies published up to 30 November 2020 and reporting on myopia and OAG diagnosis. By random-effect models, pooled OAG prevalence in a myopic population and pooled myopic OAG prevalence in a general population were generated, with 95% confidence intervals (CIs).Results: The meta-analysis encompassed five population-based studies in four countries (12,830 individuals, including 7,723 patients with myopia and 1,112 patients with OAG). In a myopic population, OAG prevalence was 4.10% (95% CI, 3.00–5.70; I2 = 93%); in a general population, myopic OAG prevalence was 1.10% (95% CI, 0.60–1.70; I2 = 94%). A visual examination of funnel plot symmetry raised a suspicion of publication bias. Notwithstanding, Begg and Mazumbar’s adjusted rank correlation test showed no such evidence (p = 0.6242).Conclusions: Our systematic review and meta-analysis returned an estimate of OAG prevalence in a myopic Northeast Asian population. Our findings will inform future glaucoma studies as well as public health guidelines for Northeast Asian populations.